Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lexagene Holdings Inc LXXGQ

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Post by Chopper1BigDogon Jan 19, 2021 11:55am
85 Views
Post# 32326579

Only for grown-ups not donkeys - AMR & LEX TEC -

Only for grown-ups not donkeys - AMR & LEX TEC - The current pandemic has underlined that everyone, across all sectors and industries, has a role to play in slowing the threat of antimicrobial resistance. In this session, the critical role of governments, researchers, industry, and the patient voice were highlighted, showing the unique perspective each brings to the AMR conversation.

Governments provide much needed investment and guidance for critical public health systems during the COVID-19 pandemic – and we need to look to how we can sustain and replicate investments that have wider application. Public health systems help drive data collection and knowledge that inform effective interventions, like infection prevention and control, and guidance for therapeutics, vaccines, and diagnostics.

Researchers, in the public and private sector, are developing vital tools that include diagnostics, therapeutics, and vaccines to combat COVID-19. We must continue investing in these types of tools to tackle the rise of antimicrobial-resistant infections.

Working across sectors and engaging industry has accelerated innovation, and civil society initiatives are ensuring access to new COVID-19 products around the world. Using a similar approach, it is critical to sharpen our focus on driving innovation for AMR and assuring these innovations are accessible to those who need them most. Finally, patients bring AMR to life by telling unique stories with their own voices. It is not just data, stats, and science; it is the very real experience that happens to patients with antimicrobial-resistant infections. Their unique experience and voices are critical in the dialogue and the fight against AMR.

Quote from the moderator, Jeremy Knox:
“We've heard a lot recently of AMR being referred to as the next pandemic following COVID down the line, characterized as one that may be slower moving but which over the longer run might be no less deadly. A sustained, collaborative response is required across multiple sectors, and across geographies to combat AMR. And, as with COVID, no single country will be safe from drug resistant infections until all countries take action.” ( This is from Center for Disease Control ( CDC ), " AMR , in light of Covid - 19 
<< Previous
Bullboard Posts
Next >>